NYSE:PRGO

Perrigo - PRGO Stock Forecast, Price & News

$35.66

-0.29 (-0.81%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $35.55
▼
$36.59
50-Day Range: $35.66
▼
$42.98
52-Week Range: $31.32
▼
$49.39

Volume: 1.18 million shs
Average Volume: 997,188 shs
Market Capitalization: $4.80 billion

P/E Ratio: N/A
Dividend Yield: 2.89%
Price Target: $51.67

Perrigo MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 44.9% Upside
$51.67 Price Target
Short Interest: Bearish
4.20% of Shares Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -1.93
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: 32.75%
From $2.29 to $3.04 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.78 out of 5 stars

Medical Sector

66th out of 1,095 stocks

Pharmaceutical Preparations Industry

17th out of 547 stocks

3.5

Analyst's Opinion

Consensus Rating
Perrigo has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $51.67, Perrigo has a forecasted upside of 44.9% from its current price of $35.66.
Amount of Analyst Coverage
Perrigo has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
4.20% of the outstanding shares of Perrigo have been sold short.
Short Interest Ratio / Days to Cover
Perrigo has a short interest ratio ("days to cover") of 4.7.
Change versus previous month
Short interest in Perrigo has recently increased by 7.81%, indicating that investor sentiment is decreasing significantly.

3.3

Dividend Strength

Dividend Yield
Perrigo pays a meaningful dividend of 2.89%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Perrigo has been increasing its dividend for 19 years.
Dividend Sustainability
Based on earnings estimates, Perrigo will have a dividend payout ratio of 34.21% next year. This indicates that Perrigo will be able to sustain or increase its dividend.

3.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Perrigo has received a 41.09% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Anti-diarrheal and intestinal anti-inflammatory medication (A07)", "Dental floss", "Antifungal medication (D01) ", "Cough and cold medication (R05)", and "Toothbrushes" products. See details.
Environmental Sustainability
The Environmental Impact score for Perrigo is -1.93.

1.9

News and Social Media Coverage

News Sentiment
Perrigo has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.
MarketBeat Follows
5 people have added Perrigo to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Perrigo insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.80% of the stock of Perrigo is held by insiders.
Percentage Held by Institutions
96.41% of the stock of Perrigo is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

2.5

Earnings and Valuation

Earnings Growth
Earnings for Perrigo are expected to grow by 32.75% in the coming year, from $2.29 to $3.04 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Perrigo is -50.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Perrigo is -50.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Perrigo has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Perrigo (NYSE:PRGO) Stock

Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe. The company also offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Receive PRGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Perrigo and its competitors with MarketBeat's FREE daily newsletter.

PRGO Stock News Headlines

September 14, 2022 | msn.com

U.S. FDA to review Perrigo's birth control pill for OTC use in November

September 14, 2022 | seekingalpha.com

Perrigo raised to Buy at Argus; expects momentum to continue amid self-care focus

September 12, 2022 | benzinga.com

Perrigo (NYSE:PRGO) – Perrigo Announces Joint FDA Advisory Committee To Review Opill Daily Oral Contracep - Benzinga

September 12, 2022 | finance.yahoo.com

UPDATE 1-U.S. FDA to review Perrigo's birth control pill for OTC use in November - Yahoo Finance

September 12, 2022 | finance.yahoo.com

PERRIGO ANNOUNCES JOINT FDA ADVISORY COMMITTEE TO REVIEW OPILL® DAILY ORAL CONTRACEPTIVE FOR OVER-THE-COUNTER (OTC) USE

September 9, 2022 | nasdaq.com

Perrigo (PRGO) Down 8.2% Since Last Earnings Report: Can It Rebound? - Nasdaq

September 8, 2022 | finance.yahoo.com

Perrigo (PRGO) Down 8.2% Since Last Earnings Report: Can It Rebound?

September 7, 2022 | cnet.com

$2 Million Baby Formula Settlement: Are You Entitled to a Check? - CNET

September 6, 2022 | investing.com

Pre-Open Movers: ADT Jumps on State Farm Deal, Bed Bath Falls on CFO's Death By Investing.com - Investing.com

September 4, 2022 | reuters.com

Perrigo Company PLC

August 22, 2022 | finance.yahoo.com

Is Perrigo (PRGO) a Smart Investment Choice?

August 18, 2022 | nasdaq.com

Perrigo Enters Oversold Territory

August 18, 2022 | nasdaq.com

Interesting PRGO Put And Call Options For October 21st

August 17, 2022 | finance.yahoo.com

PERRIGO RELEASES STATEMENT ON RECENT MARKET TRADING ACTIVITY

August 16, 2022 | bloomberg.com

Zantac Cancer Case in US Settles for $500,000 (PRGO, TEVA) - Bloomberg

August 10, 2022 | seekingalpha.com

Perrigo (PRGO) CEO, Murray Kessler on Q2 2022 Results - Earnings Call Transcript - Seeking Alpha

August 9, 2022 | investing.com

Perrigo Reports In-Line Q2 EPS By Investing.com - Investing.com

August 9, 2022 | finance.yahoo.com

Perrigo's (PRGO) Q2 Earnings Misses by a Cent, Sales Beat

August 9, 2022 | in.investing.com

Perrigo Reports In-Line Q2 EPS By Investing.com - Investing.com India

August 9, 2022 | finance.yahoo.com

Perrigo (PRGO) Lags Q2 Earnings Estimates

August 9, 2022 | au.investing.com

Perrigo Reports In-Line Q2 EPS By Investing.com - Investing.com Australia

August 8, 2022 | seekingalpha.com

Perrigo Q2 2022 Earnings Preview (NYSE:PRGO) - Seeking Alpha

August 6, 2022 | bloomberg.com

Jefferies Hires JPMorgan Chase's Co-Head of North America M&A - Bloomberg

August 3, 2022 | finance.yahoo.com

Here’s What Makes Perrigo (PRGO) a Great Investment Option

August 2, 2022 | nasdaq.com

Perrigo (PRGO) to Report Q2 Earnings: What's in the Cards? - Nasdaq

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive PRGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Perrigo and its competitors with MarketBeat's FREE daily newsletter.

PRGO Company Calendar

Last Earnings: 8/09/2022
Ex-Dividend for 9/20 Dividend: 9/01/2022
Dividend Payable: 9/20/2022
Today: 10/02/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NYSE:PRGO
CUSIP: 71429010
CIK: 1585364
Web: www.perrigo.com
Phone: (531) 709-4000
Fax: 269-673-9128
Employees: 9,900
Year Founded: 1887

Price Target and Rating

Average Stock Price Forecast: $51.67
High Stock Price Forecast: $55.00
Low Stock Price Forecast: $46.00
Forecasted Upside/Downside: +44.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 15.57
P/E Growth: N/A
Net Income: $-68,900,000.00
Net Margins: -2.17%
Pretax Margin: 6.39%
Return on Equity: 4.87%
Return on Assets: 2.32%

Debt

Debt-to-Equity Ratio: 0.84
Current Ratio: 2.61
Quick Ratio: 1.55

Sales & Book Value

Annual Sales: $4.14 billion
Price / Sales: 1.16
Cash Flow: $4.34 per share
Price / Cash Flow: 8.21
Book Value: $38.51 per share
Price / Book: 0.93

Miscellaneous

Outstanding Shares: 134,620,000
Free Float: 133,541,000
Market Cap: $4.80 billion
Optionable: Optionable
Beta: 0.92

Social Links

Key Executives

Mr. Murray S. Kessler (Age 62)
CEO, Pres & Director
Comp: $2.78M

Mr. Svend Andersen (Age 60)
Exec. VP & Pres of Consumer Self-Care International
Comp: $1.18M

Mr. James E. Dillard III (Age 58)
Exec. VP & Pres of Consumer Self-Care Americas
Comp: $999.36k

Mr. Eduardo Guarita Bezerra (Age 47)
Exec. VP & CFO

Mr. Ronald C. Janish (Age 56)
Chief Transformation Officer and Exec. VP of Global Operations & Supply Chain

Mr. Shannon Hukill
Sr. Director of Technical Operations

Mr. Thomas M. Farrington (Age 65)
Chief Information Officer & Exec. VP

Ms. Alison Ives
Exec. VP & Chief Scientific Officer

Mr. Bradley Joseph
VP of Global Investor Relations & Corp. Communications

Ms. Kyle L. Hanson (Age 57)
Exec. VP, Gen. Counsel & Corp. Sec.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PRGO Stock - Frequently Asked Questions

Should I buy or sell Perrigo stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Perrigo in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" PRGO shares.
View PRGO analyst ratings or view top-rated stocks.
What is Perrigo's stock price forecast for 2022?: 3 Wall Street research analysts have issued twelve-month price targets for Perrigo's stock. Their PRGO share price forecasts range from $46.00 to $55.00. On average, they expect the company's stock price to reach $51.67 in the next year. This suggests a possible upside of 44.9% from the stock's current price.
View analysts price targets for PRGO or view top-rated stocks among Wall Street analysts.
How have PRGO shares performed in 2022?: Perrigo's stock was trading at $38.90 at the beginning of 2022. Since then, PRGO stock has decreased by 8.3% and is now trading at $35.66.
View the best growth stocks for 2022 here.
When is Perrigo's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our PRGO earnings forecast.
How were Perrigo's earnings last quarter?: Perrigo Company plc (NYSE:PRGO) posted its earnings results on Tuesday, August, 9th. The company reported $0.43 earnings per share for the quarter, missing analysts' consensus estimates of $0.44 by $0.01. The business had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.06 billion. Perrigo had a positive trailing twelve-month return on equity of 4.87% and a negative net margin of 2.17%. Perrigo's quarterly revenue was up 14.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.50 EPS.
Read the conference call transcript.
How often does Perrigo pay dividends? What is the dividend yield for Perrigo?: Perrigo announced a quarterly dividend on Tuesday, August 2nd. Shareholders of record on Friday, September 2nd will be given a dividend of $0.26 per share on Tuesday, September 20th. This represents a $1.04 dividend on an annualized basis and a yield of 2.92%. The ex-dividend date is Thursday, September 1st.
Read our dividend analysis for PRGO.
Is Perrigo a good dividend stock?: Perrigo (NYSE:PRGO) pays an annual dividend of $1.04 per share and currently has a dividend yield of 2.89%.
Read our dividend analysis for PRGO.
What guidance has Perrigo issued on next quarter's earnings?: Perrigo issued an update on its FY 2022 earnings guidance on Tuesday, September, 13th. The company provided EPS guidance of $2.25-$2.35 for the period. The company issued revenue guidance of $4.49 billion-$4.53 billion, compared to the consensus revenue estimate of $4.49 billion.

What is Murray S. Kessler's approval rating as Perrigo's CEO?: 38 employees have rated Perrigo Chief Executive Officer Murray S. Kessler on Glassdoor.com. Murray S. Kessler has an approval rating of 83% among the company's employees.
What other stocks do shareholders of Perrigo own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Perrigo investors own include Teva Pharmaceutical Industries (TEVA), Gilead Sciences (GILD), Mylan (MYL), AbbVie (ABBV), Allergan (AGN), Intel (INTC), Johnson & Johnson (JNJ), Netflix (NFLX), QUALCOMM (QCOM) and Amgen (AMGN).
What is Perrigo's stock symbol?: Perrigo trades on the New York Stock Exchange (NYSE) under the ticker symbol "PRGO."
How do I buy shares of Perrigo?: Shares of PRGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Perrigo's stock price today?: One share of PRGO stock can currently be purchased for approximately $35.66.
How much money does Perrigo make?: Perrigo (NYSE:PRGO) has a market capitalization of $4.80 billion and generates $4.14 billion in revenue each year. The company earns $-68,900,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis.
How many employees does Perrigo have?: The company employs 9,900 workers across the globe.
Does Perrigo have any subsidiaries?: The following companies are subsidiares of Perrigo: 010414 UK Limited, 251211 UK Limited, Abtei Omega Pharma GmbH, Aco Hud Nordic AB, Adriatic BST Trgovina in Storitve D.o.o., Adriatic Distribution doo Beograd, Agis Industries, Algorithmics Risk Management Limited, Arginet Investments and Property (2003) Ltd., Athena Neurosciences LLC, Aurora Pharmaceuticals Pty Ltd, Biover NV, Blue Wolf Global Limited, Bluewolf International Limited, Brunel Healthcare Manufacturing Limited, CP Kayak Holdings Inc., CanNegev Ltd, Chefaro Ireland Designated Activity Company, Cinetic Laboratories Argentina SA, Cleversafe UK Limited, Cosmediet - Biotechnie SAS, Despharma Kft., Elan Corporation, Elan Europa Finance S.á r.l., Elan International Services Limited, Elan Pharmaceuticals LLC, Fera Pharmaceuticals, Galpharm Healthcare Limited, Galpharm International, Galpharm International Limited, Geiss Destin & Dunn, Gelcaps Exportadora de Mexico S.A. de C.V., Gr8ness LLC, HRA Pharma, Habsont Unlimited Company, Heartbeat Experts Limited, IBM GF international Treasury Company, IBM International Treasury Services Unlimited Company, IBM Netherlands Treasury B.V., Interdelta S.A., International Business Machines Limited, Irish Biosciences Venture Capital Fund, JB Laboratories, JLR Pharma S.A., Jaico R.D.P. NV, Jewel Consumer Care Pvt. Ltd., Kazmira LLC, Kenexa Global Recruitment Services Limited, Kenexa Quorum Holdings Limited, Kenexa Technology LLC, Kiteacre Limited, L. Perrigo Company, Laboratoire de la Mer SAS, Laboratoires Omega Pharma France SAS, Laboratorios DIBA S.A., Laboratorios Diba, Luxembourg Investment Company 289 Sàrl, MH (UK) Limited, Medgenix Benelux NV, Monksland Holdings B.V., Naturwohl Pharma GmbH, ORION Laboratories, Oce Bio BV, Oce-Bio Nederland B.V., Omega Alpharm Cyprus Ltd., Omega Pharma, Omega Pharma AS, Omega Pharma Australia Pty Ltd, Omega Pharma Austria Healthcare GmbH, Omega Pharma Baltics SIA, Omega Pharma Belgium NV, Omega Pharma Capital NV, Omega Pharma Deutschland GmbH, Omega Pharma GmbH, Omega Pharma Hellas SA Health and Beauty Products, Omega Pharma Hungary Kft., Omega Pharma Innovation & Development NV, Omega Pharma International NV, Omega Pharma Limited, Omega Pharma Luxembourg SarL, Omega Pharma Manufacturing GmbH & Co. KG, Omega Pharma Manufacturing Verwaltungs GmbH, Omega Pharma Nederland B.V., Omega Pharma Trading NV, Omega Pharma s.r.o., Omega Teknika Designated Activity Company, OmegaLabs (Pty) Ltd, Oniqua Europe Limited, Optevia Limited, Orion Laboratories (NZ) Ltd., Orion Laboratories PTY Limited, P-Direct NL B.V., P2C Inc., PBM Canada Holdings LLC, PBM China Holdings LLC, PBM Foods LLC, PBM Holdings LLC, PBM International Holdings LLC, PBM Mexico Holdings LLC, PBM Nutritionals LLC, PBM Products, PBM Products LLC, PBM Products Mexico S de R.L. de C.V., PMI Branded Pharmaceuticals Inc., Paddock Laboratories, Paracelsia Pharma GmbH, Perrigo Asia Holding Company Ltd., Perrigo Australian Holding Company II PTY Limited, Perrigo Bulgaria OOD, Perrigo China Business Trust, Perrigo China Business Trustee LLC, Perrigo Company, Perrigo Company Charitable Foundation, Perrigo Company of Tennessee, Perrigo Company plc, Perrigo Corporation Designated Activity Company, Perrigo Danmark A/S, Perrigo Diabetes Care LLC, Perrigo Direct Inc., Perrigo España SA, Perrigo Europe Invest NV, Perrigo Finance (US) LLC, Perrigo Finance Unlimited Company, Perrigo Florida Inc., Perrigo France SAS, Perrigo Global Holdings Inc., Perrigo Holding NV, Perrigo Holdings Unlimited Company, Perrigo International Finance Designated Activity Company, Perrigo International Holdings II Inc., Perrigo International Holdings LLC, Perrigo International Inc., Perrigo International Insurance Limited, Perrigo Ireland 1 Designated Activity Company, Perrigo Ireland 10 Unlimited Company, Perrigo Ireland 11 DAC, Perrigo Ireland 12 Designated Activity Company, Perrigo Ireland 13 Designated Activity Company, Perrigo Ireland 2 Designated Activity Company, Perrigo Ireland 3 Designated Activity Company, Perrigo Ireland 4 Unlimited Company, Perrigo Ireland 5 Unlimited Company, Perrigo Ireland 6 Unlimited Company, Perrigo Ireland 7 Designated Activity Company, Perrigo Ireland 8 Designated Activity Company, Perrigo Ireland 9 Unlimited Company, Perrigo Ireland Holding Company B.V., Perrigo Ireland Management Designated Activity Company, Perrigo Israel Enterprises & Investments Ltd., Perrigo Israel Holdings II B.V., Perrigo Israel Opportunities II Ltd., Perrigo Israel Trading Limited Partnership, Perrigo Italia S.r.l, Perrigo Kişisel Bakım Ürünleri Sanayi ve Ticaret Limited Şirketi, Perrigo LLC, Perrigo Laboratories India Private Limited, Perrigo Management Company, Perrigo Mexico Holding S.A. de C.V., Perrigo Mexico Investment Holdings LLC, Perrigo Netherlands B.V., Perrigo Netherlands Finco 1 Coöperatief U.A., Perrigo Netherlands Finco 2 B.V., Perrigo Netherlands International Partnership C.V., Perrigo New York Inc., Perrigo Norge AS, Perrigo Oral Health Care Holdings Inc., Perrigo Pharma Holding Nederland BV, Perrigo Pharma International Designated Activity Company, Perrigo Pharma Limited, Perrigo Poland Sp.z.o.o, Perrigo Portugal LDA, Perrigo Research & Development Company, Perrigo România S.R.L., Perrigo Sales Corporation, Perrigo Science Eight Unlimited Company, Perrigo Science One Designated Activity Company, Perrigo Suomi Oy, Perrigo Sverige AB, Perrigo Trading (Shanghai) Co. Ltd., Perrigo UK Acquisition Limited, Perrigo UK Finco Limited Partnership, Perrigo Ukraine LLC, Perrigo Ventures Limited Partnership, Perrigo de Mexico S.A. de C.V., Perrigo do Brasil Farmaceutica Ltda., Pharma Clal (1983) Ltd., Promontory Financial Group (UK) Limited, Quimica y Farmacia S.A. de C.V., Ranir, Ranir (Holdings) Limited, Ranir Changshu Oral Care CO. Ltd., Ranir Global Holdings LLC, Ranir LLC, Ranir Limited, Resilient Systems Europe Limited, Richard Bittner AG, Rosemont Pharmaceuticals, Rubicon Healthcare Holdings Pty Ltd, SPSS Limited, Samenwerkende Apothekers Nederland B.V., ScarAway, Silverpop Systems Limited, Simpler Consulting Limited, Solent Dental Company Limited, Solent Oral Care Limited, Sterling Commerce (UK) Limited, The Analytic Sciences Corporation Limited, The Learning Pharmacy Limited, The Weather Channel Global Media Limited, Totalcare International Corp, Transitive Corporation Limited, Transitive Limited, Truven Health Analytics UK Limited, Velcera, Weather Services International Limited, Wrafton Laboratories, Wrafton Laboratories Limited, Zibo Xinhua - Perrigo Pharmaceutical Company Ltd., i2 Holdings Limited, i2 Intermediate Holdings Limited, and i2 Limited.
Read More
How can I contact Perrigo?: Perrigo's mailing address is THE SHARP BUILDING HOGAN PLACE, DUBLIN L2, 49010. The official website for the company is www.perrigo.com. The company can be reached via phone at (531) 709-4000, via email at bradley.joseph@perrigo.com, or via fax at 269-673-9128.

This page (NYSE:PRGO) was last updated on 10/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Perrigo - PRGO Stock Forecast, Price & News

Perrigo MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month